PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNotices
BuyersSuppliersNotices
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. Sobi (Swedish Orphan Biovitrum Ltd)
S(

Sobi (Swedish Orphan Biovitrum Ltd)

Cambridge
Large

Sobi is dedicated to developing and delivering innovative treatments for people living with rare diseases, focusing on specialized treatment areas such as inflammation, genetics & metabolism, and haemophilia.

sobi-uk.co.uk ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£697.0m
Live
18
Buyers
3
12m
£529.1m
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities2
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts18 / 30
  • Top buyers3
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — Sobi (Swedish Orphan Biovitrum Ltd)Updated 13 Jul 2026

At a glance · for buyers and watchdogs

Sobi (Swedish Orphan Biovitrum Ltd) has won £697.0m across 3 public-sector buyers, with 18 live contracts. No active Companies House risk flags.

Why: top buyer NHS England at 100% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
18 of 30Live contracts
100%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value

Commitments mapped to the Government Social Value Model themes.

⚑ Self-reported
—

No social-value commitments yet

Jobs, skills, environmental, inequality and community commitments appear here once a claimed supplier attributes them to awarded contracts, or once we detect them on the supplier’s website.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Services · 2
Innovative TreatmentsSobi provides and develops innovative treatments for rare immunological diseases and specialty rare diseases. ↗Patient Support ProgramsSobi co-creates innovative solutions including patient support programmes and digital tools based on patient needs. ↗
Frameworks & DPS · 2 from notices
  • NHS Framework Agreement, Branded Medicines for London and South of EnglandNHS England · £13.3m
  • NHS Framework for the North of England, Branded MedicineNHS England · £7.7m

Extracted automatically from sobi-uk.co.uk on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 18 live · 12 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS National Branded Interim - 1 June 2026
NHS England—01 Jun 2026£529.1m1.9 yrspending
NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025
NHS England3360000001 Sept 2025£47.0m2 yrsLive
NHS Branded Medicines Tranche Framework for London and South of England
NHS England3360000001 Sept 2024£13.1m2 yrsLive
NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)
NHS England3360000001 Jun 2024£0.023 yrsLive
NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024
NHS England3360000001 Mar 2024£17.6m2.5 yrsLive
NHS South of England Branded Medicines - Tranche A - September 2023
NHS England3360000001 Sept 2023£7.6m2 yrsClosed
NHS London Branded Medicines - Tranche B - September 2023
NHS England3360000001 Sept 2023£6.4m2 yrsClosed
NHS Midland & East Branded Medicines, Tranche B & Annual Tranche
NHS England3360000001 Mar 2023£13.7m2 yrsClosed
NHS Framework for North of England Branded Medicines Tranche A & Annual Tranche
NHS England3360000001 Mar 2023£9.0m2 yrsClosed
NHS National Generic Pharmaceuticals Wave 14a
NHS England3360000001 Feb 2023£2.1m2 yrsClosed
Total live value £77.7m · mean award £23.2m1–10 of 30

Top buyers · 3 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
25 contracts
100%
since 2021
2
Regional Business Services Organisation Procurement and Logistics Service
1 contract
0%
3
The NHS Commissioning Board (operating under the name of NHS England)
4 contracts
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire25 contracts
100%
Northern Ireland1 contract
0%
North West4 contracts
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). Sobi (Swedish Orphan Biovitrum Ltd) highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
S(
Sobi (Swedish Orphan Biovitrum Ltd)
No£529.1m—
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m22
JA
Janssen-Cilag Ltd
Yes£117.6m18
AB
AbbVie Ltd
Yes£95.2m12
TA
Thornton and Ross Ltd
Yes£72.5m12
AC
ACCORD-UK LTD
Yes£71.2m21
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Dec 2024
Confirmation statement
Up to date
Next due 22 Feb 2027
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
04369760
Status
Active
Type
Private limited
Incorporated
08 Feb 2002
Reg. office
Suite 2, Building 3, Riverside Suite Granta Park, Great Abington, Cambridge, CB21 6AD
SIC codes
21200
Last accounts
31 Dec 2024
Next accounts due
30 Sept 2026

Directors & PSC

  • KNOTT, Steve Wesley Andrew — secretary
    Appointed 29 Nov 2024
  • HALL, Sharon — director
    Appointed 02 Mar 2023
  • FAHMY, Soufiane — director
    Appointed 02 Nov 2020
  • STENQVIST, Henrik — director
    Appointed 20 Jul 2018
  • Swedish Orphan Biovitrum International Ab (Publ) — person with significant control
    ownership of shares 75 to 100 percent

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
SWEDISH ORPHAN BIOVITRUM LTD
04369760 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.